Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ann Oncol. 2002 Feb;13(2):197-207.

Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?

Author information

  • 1Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium.

Abstract

Despite almost 30 years of clinical cancer research, the true impact of second and subsequent lines of chemotherapy on the outcome of metastatic breast cancer patients, especially on the duration of survival, is still unknown. In the virtually incurable metastatic setting, issues like quality of life and patients' preferences gain particular relevance. At the turn of the century, in-depth rethinking of the design of clinical trials run in this challenging disease setting appears to be warranted.

PMID:
11885995
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire
    Loading ...
    Write to the Help Desk